November 28, 2016 - By Ellis Scott
Cannabis Science Inc (OTCMKTS:CBIS) recorded consecutive gains, during the November 23 and November 25 trading session, adding approximately $0.01 to its share value, prior to the weekend. The stock has been fluctuating in the market, during the last 1-week, recording an intra-week high of $0.04 and a low of $0.028 per share. The fluctuation has been quite unexpected, given that they company’s CEO, Raymond C. Dabney, recently delivered a presentation at the Harvard Medical School, which turned out to be a great success. The school representatives have even hinted at the possibility of potential partnerships, in the near future.
In a recent press release CBIS announced that following the successful presentation at the Harvard Medical School, Dr. Wilfred F. Ngwa, the director of Global Health Catalyst, at the institution, hinted at the possibility of mutually beneficial partnerships, between the company and the school. The company also noted that the director initiated discussions for conducting joint research and other beneficial opportunities. It should be noted here that Mr. Dabney’s presentation provided an overview of CBIS and the Cannabis Science Research Foundation. Moreover, the presentation focused on the science behind cannabis based therapies and they target critical ailments and are confirmed to have the ability to kill cancerous cells.
Dr. Ngwa stated, “I must say that we were pleasantly surprised with the depth of knowledge, clearly targeted missions, and direct plan of action delivered by Cannabis Science. We invited Mr. Dabney and his team to discuss the drug development success and progress the company had made over the years. Partnerships between the CBIS team and scientists here at the DF/HCC are expected to bring a deeper understanding of the potential effectiveness of cannabinoids in the treatment of cancer and other chronic diseases.
The announcement comes at a time when Cannabis Science is working to initiate a long awaited study, for patients suffering from various failing lung functions. The company plans to particularly target patients whose conditions are a result of cancers or bronchitis. At the moment, CBIS is waiting for the completion of its First Lab and Extraction site, which the company believes would be completed this month. Moreover, Cannabis Science is also focusing on the development of delivery systems, which would provide the most benefits to the patient.
“While we here at Cannabis Science are committed to the development of cannabinoid cased medications in this relatively new modern time of medical marijuana applications for health benefits, we also realize the importance of method of delivery and the ability to target these medications to the problem areas,” stated Mr. Dabney
Cannabis Science is a drug development company, with a unique understanding of metabolic processes. Moreover, the company focuses on ailments, for which current treatments and understanding remain inadequate. CBIS is one of the most promising companies in the medical cannabis space and the recent statement from Mr. Ngwa proves it. However, a definitive agreement between the company and the Harvard Medical School would further improve the prospects of CBIS.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Ellis Scott